[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

BridgeBio Pharma insider filing: Maricel Apuli, the company's Chief Accounting Officer, reported a transaction dated 08/16/2025 related to the vesting of restricted stock units. The filing shows 4,781 shares of common stock were withheld to satisfy tax obligations at a reported price of $51.32 per share following the vesting of 9,409 RSUs.

After the withholding, Ms. Apuli beneficially owns 137,078 shares of BridgeBio Pharma (BBIO) on a direct basis. The Form 4 is a routine disclosure of compensation-related share withholding and does not include derivative transactions or other purchases or sales.

Positive

• Continued ownership: Reporting person retains 137,078 shares after withholding, indicating ongoing insider ownership.
• Routine compliance: Form 4 timely discloses a tax-withholding transaction tied to RSU vesting, meeting reporting obligations.

Negative

• Reduction in direct holdings: 4,781 shares were withheld to satisfy taxes, lowering beneficially owned shares from the pre-transaction amount.
• No additional context: Filing does not state the pre-withholding share total explicitly, so change magnitude must be inferred from RSU vesting note.

Insights

Financial Analyst

TL;DR: Routine tax-withholding on vested RSUs; small reduction in holdings, no open-market sale or new compensation granted.

The Form 4 reports a Code F transaction indicating shares were withheld to satisfy tax withholding on vested RSUs. Withholding of 4,781 shares at $51.32 reduced Ms. Apuli's direct holdings to 137,078 shares. This is a common administrative action tied to compensation and typically has negligible impact on company valuation or control. There are no reported open-market dispositions or derivative exercises in this filing.

Corporate Governance Expert

TL;DR: Administrative withholding for tax purposes on RSU vesting; disclosure aligns with Section 16 reporting requirements.

The filing fulfills Section 16(a) transparency by disclosing withholding associated with the vesting of 9,409 RSUs. The reporting person is an officer (Chief Accounting Officer) and remains a direct holder of 137,078 shares after withholding. This disclosure is routine governance practice and does not indicate a change in board composition, control intent, or unusual insider trading activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Apuli Maricel

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/16/2025		F		4,781(1)	D	$51.32	137,078	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,409 shares of Common Stock underlying the Reporting Person's Restricted Stock Units.

	/s/ Maricel Apuli	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Maricel Apuli report on Form 4 for BBIO?

The Form 4 reports a Code F transaction on 08/16/2025 where 4,781 shares were withheld to satisfy tax obligations related to vested RSUs.

How many BridgeBio (BBIO) shares does Maricel Apuli own after the transaction?

After the withholding, Ms. Apuli beneficially owns 137,078 shares on a direct basis.

What price is listed for the shares withheld in the Form 4?

The filing reports a withholding price of $51.32 per share for the 4,781 shares.

Why were shares withheld in this Form 4 filing?

The 4,781 shares were withheld to satisfy the reporting person’s tax obligation in connection with the vesting of 9,409 RSUs, per the filing explanation.

Does the Form 4 report any open-market sales or option exercises by the officer?

No. The filing shows only a tax-withholding (Code F) related to RSU vesting and does not report open-market sales or derivative transactions.